GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ReNeuron Group PLC (LSE:RENE) » Definitions » Equity-to-Asset

ReNeuron Group (LSE:RENE) Equity-to-Asset : 0.38 (As of Sep. 2023)


View and export this data going back to 2005. Start your Free Trial

What is ReNeuron Group Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. ReNeuron Group's Total Stockholders Equity for the quarter that ended in Sep. 2023 was £2.42 Mil. ReNeuron Group's Total Assets for the quarter that ended in Sep. 2023 was £6.42 Mil. Therefore, ReNeuron Group's Equity to Asset Ratio for the quarter that ended in Sep. 2023 was 0.38.

The historical rank and industry rank for ReNeuron Group's Equity-to-Asset or its related term are showing as below:

LSE:RENE' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.38   Med: 0.78   Max: 0.96
Current: 0.38

During the past 13 years, the highest Equity to Asset Ratio of ReNeuron Group was 0.96. The lowest was 0.38. And the median was 0.78.

LSE:RENE's Equity-to-Asset is ranked worse than
71.79% of 1567 companies
in the Biotechnology industry
Industry Median: 0.66 vs LSE:RENE: 0.38

ReNeuron Group Equity-to-Asset Historical Data

The historical data trend for ReNeuron Group's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ReNeuron Group Equity-to-Asset Chart

ReNeuron Group Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.74 0.65 0.75 0.57 0.52

ReNeuron Group Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.66 0.57 0.51 0.52 0.38

Competitive Comparison of ReNeuron Group's Equity-to-Asset

For the Biotechnology subindustry, ReNeuron Group's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ReNeuron Group's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ReNeuron Group's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where ReNeuron Group's Equity-to-Asset falls into.



ReNeuron Group Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

ReNeuron Group's Equity to Asset Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Equity to Asset (A: Mar. 2023 )=Total Stockholders Equity/Total Assets
=5.057/9.645
=0.52

ReNeuron Group's Equity to Asset Ratio for the quarter that ended in Sep. 2023 is calculated as

Equity to Asset (Q: Sep. 2023 )=Total Stockholders Equity/Total Assets
=2.421/6.423
=0.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ReNeuron Group  (LSE:RENE) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


ReNeuron Group Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of ReNeuron Group's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


ReNeuron Group (LSE:RENE) Business Description

Traded in Other Exchanges
Address
Pencoed Business Park, Pencoed, Bridgend, GBR, CF35 5HY
ReNeuron Group PLC is engaged in the field of biotechnology. Its core activities include the research and clinical development of cell-based therapeutics. The company product pipeline includes the human retinal progenitor cell line (hRPC) and CTX neural cell line. It derives revenue from UK and U.S. The company is mainly focusing on the treatment of stroke disability, inherited retinal diseases, and cancer.